Powering Europe's pandemic response: EVI and partners to offer vaccine R&D expertise and resources to applicant developers through ISIDORe II

01 June 2026

The European Vaccine Initiative (EVI) is proud to announce its continued contribution to Europe's pandemic preparedness infrastructure as the newly launched ISIDORe II project gets underway. ISIDORe II (Integrated Services for Infectious Disease Outbreak Research II), coordinated by ERINHA and funded through Horizon Europe with a budget of €10.5 million over three years, aims to transform an emergency-driven initiative into a sustainable European capacity for preparedness research. EVI attended the virtual project kick-off meeting Monday, 8 June 2026.

Through TRANSVAC, the European vaccine research infrastructure, EVI leads a comprehensive portfolio of vaccine research and development services which is available to the scientific community under the ISIDORe II framework. These include:

• Vaccine adjuvant and formulation services:  access to a range of mucosal and parenteral adjuvants and expertise in optimising vaccine formulations for enhanced immunogenicity;

• mRNA vaccine development: cutting-edge mRNA platform technologies for next-generation vaccine design and testing;

• In vivo infection models: validated animal models for vaccine immunogenicity and efficacy assessment, from small animals through non-human primates;

• Immune monitoring services for infectious disease research: to support the immunological assessment of vaccine candidates and infection responses;

• Vaccine process development and preclinical production services: preclinical production and up-scaling of manufacturing processes for novel vaccine candidates.

• 
  

Integrating these services within the larger ISIDORe II services catalogue enables support for vaccine developers across the preclinical procepathway. These services are delivered in close collaboration with longstanding TRANSVAC partners: the Vaccine Formulation Institute (VFI, Switzerland), the Statens Serum Institut (SSI, Denmark), iBET – Instituto de Biologia Experimental e Tecnológica (Portugal), and the Helmholtz Centre for Infection Research (HZI, Germany).

Building on the achievements of the original ISIDORe project, which supported 174 research projects and provided access to more than 300 services, ISIDORe II is designed as a leaner, more operationally integrated consortium reinforcing long-term sustainability and alignment with European preparedness policies.

EVI's involvement reflects its strategic commitment to making world-class vaccine development expertise broadly accessible. ISIDORe II will provide researchers with coordinated access to high-containment facilities, advanced technologies, scientific expertise, biological resources, and data infrastructures needed to address threats from epidemic- and pandemic-prone pathogens.

Researchers seeking access to TRANSVAC services through ISIDORe II are invited to consult the ISIDORe service catalogue and upcoming calls for applications at isidore-project.eu.

ISIDORe II is funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.